Functions of p53 in metabolism and invasion

Biochemical Society Transactions

Volumn 37, Issue 3, 2009, Pages 511-517

  Vousden, Karen H ^a  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

Cancer; Invasion; Metabolism; Murine double minute 2 (MDM2); P53; Tumour suppression

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER INVASION; FAMILIAL CANCER; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; METABOLIC REGULATION; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STABILITY; PROTEIN TARGETING; RISK FACTOR; SENESCENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ANIMALS; APOPTOSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MUTATION; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MDM2; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

MURINAE;

EID: 67749116522     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST0370511     Document Type: Article

References (84)

1. Lowe, S.W., Cepero, E. and Evan, G. (2004) Intrinsic tumour suppression. Nature 432, 307-315
2. Vogelstein, B., Lane, D. and Levine, A.J. (2000) Surfing the p53 network. Nature 408, 307-310
3. Donehower, L.A., Harvey, M., Slagle, B.L., McArthur, M.J., Montgomery, Jr, C.A., Butel, J.S. and Bradley, A. (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 356, 215-221
4. Purdie, C.A., Harrison, D.J., Peter, A., Dobbie, L., White, S., Howie, S.E., Salter, D.M., Bird, C.C., Wyllie, A.H., Hooper, M.L. et al. (1994) Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. Oncogene 9, 603-609
5. Jacks, T., Remington, L., Williams, B.O., Schmitt, E.M., Halachmi, S., Bronson, R.T. and Weinberg, R.A. (1994) Tumour spectrum analysis in p53-mutant mice. Curr. Biol. 4, 1-7
6. Hamroun, D., Kato, S., Ishioka, C., Claustres, M., Beroud, C. and Soussi, T. (2006) The UMD TP53 database and website: update and revisions. Hum. Mutat. 27, 14-20
7. Münger, K., Scheffner, M., Huibregtse, J.M. and Howley, P.M. (1992) Interactions of HPV E6 and E7 with tumour suppressor gene products. Cancer Surv. 12, 197-217
8. Scheffner, M., Werness, B.A., Huibregtse, J.M., Levine, A.J. and Howley, P.M. (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63, 1129-1136
9. Crook, T., Wrede, D., Tidy, J.A., Mason, W.P., Evans, D.J. and Vousden, K.H. (1992) Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours. Lancet 339, 1070-1073
10. The Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068
11. Varley, J.M. (2003) Germline TP53 mutations and Li-Fraumeni syndrome. Hum. Mutat. 21, 313-320
12. Vousden, K.H. (2002) Activation of the p53 tumor suppressor gene. Biochem. Biophys. Acta 1602, 47-59
13. Meulmeester, E. and Jochemsen, A.G. (2008) p53: a guide to apoptosis. Curr. Cancer Drug Targets 8, 87-97
14. Gatz, S.A. and Wiesmuller, L. (2006) p53 in recombination and repair. Cell Death Differ. 13, 1003-1016
15. Martins, C.P., Brown-Swigart, L. and Evan, G.I. (2006) Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127, 1323-1334
16. Ventura, A., Kirsch, D.G., McLaughlin, M.E., Tuveson, D.A., Grimm, J., Lintault, L., Newman, J., Reczek, E.E., Weissleder, R. and Jacks, T. (2007) Restoration of p53 function leads to tumour regression in vivo. Nature 445, 661-665
17. Xue, W., Zender, L., Miething, C., Dickins, R.A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C. and Lowe, S.W. (2007) Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656-660
18. Riley, T., Sontag, E., Chen, P. and Levine, A. (2008) Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell Biol. 9, 402-412
19. Murray-Zmijewski, F., Slee, E.A. and Lu, X. (2008) A complex barcode underlies the heterogeneous response of p53 to stress. Nat. Rev. Mol. Cell Biol. 9, 702-712
20. 1 arrest in human cancer cells. Cancer Res. 55, 5187-5190
21. CIP1/WAF1 gene in normal diploid human fibroblasts. Science 277, 831-834
22. Marusyk, A., Wheeler, L.J., Mathews, C.K. and DeGregori, J. (2007) p53 mediates senescence-like arrest induced by chronic replicational stress. Mol. Cell. Biol. 27, 5336-5351
23. Garner, E. and Raj, K. (2008) Protective mechanisms of p53-p21-pRb proteins against DNA damage-induced cell death. Cell Cycle 7, 1-6
24. Cory, S. and Adams, J.M. (2002) The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2, 647-656
25. Yu, J. and Zhang, L. (2003) No PUMA, no death: implications for p53-dependent apoptosis. Cancer Cell 4, 248-249
26. Moll, U.M., Wolff, S., Speidel, D. and Deppert, W. (2005) Transcription-independent pro-apoptotic functions of p53. Curr. Opin. Cell Biol. 17, 631-636
27. Chipuk, J.E., Bouchier-Hayes, L., Kuwana, T., Newmeyer, D.D. and Green, D.R. (2005) PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 309, 1732-1735
28. Tasdemir, E., Maiuri, M.C., Galluzzi, L., Vitale, I., Djavaheri-Mergny, M., D'Amelio, M., Criollo, A., Morselli, E., Zhu, C., Harper, F. et al. (2008) Regulation of autophagy by cytoplasmic p53. Nat. Cell Biol. 10, 676-687
29. Crighton, D., Wilkinson, S., O'Prey, J., Syed, N., Harrison, P.R., Gasco, M., Garrone, O., Crook, T. and Ryan, K.M. (2006) DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 14, 121-134
30. Horn, H.F. and Vousden, K.H. (2007) Coping with stress: multiple ways to activate p53. Oncogene 26, 1306-1316
31. Tang, Y., Zhao, W., Chen, Y., Zhao, Y. and Gu, W. (2008) Acetylation is indispensable for p53 activation. Cell 133, 612-626
32. Brooks, C.L. and Gu, W. (2006) p53 ubiquitination: Mdm2 and beyond. Mol. Cell 21, 307-315
33. Kubbutat, M.H.G., Jones, S.N. and Vousden, K.H. (1997) Regulation of p53 stability by Mdm2. Nature 387, 299-303
34. Haupt, Y., Maya, R., Kazaz, A. and Oren, M. (1997) Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299
35. Montes de Oca Luna, R., Wagner, D.S. and Lozano, G. (1995) Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378, 203-206
36. Jones, S.N., Roe, A.E., Donehower, L.A. and Bradley, A. (1995) Rescue of embyonic lethality in Mdm2-deficient mice by absence of p53. Nature 378, 206-208
37. Ringshausen, I., O'Shea, C.C., Finch, A.J., Swigart, L.B. and Evan, G.I. (2006) Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 10, 501-514
38. Stommel, J.M. and Wahl, G.M. (2004) Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. EMBO J. 23, 1547-1556
39. Lavin, M.F. and Gueven, N. (2006) The complexity of p53 stabilization and activation. Cell Death Differ. 13, 941-950
40. Sherr, C.J. and Weber, J.D. (2000) The ARF/p53 pathway. Curr. Opin. Genet. Dev. 10, 94-99
41. Lohrum, M.A., Ludwig, R.L., Kubbutat, M.H.G., Hanlon, M. and Vousden, K.H. (2003) Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 3, 577-587
42. Dai, M.S. and Lu, H. (2004) Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J. Biol. Chem. 279, 44475-44482
43. Vassilev, L.T. (2007) MDM2 inhibitors for cancer therapy. Trends Mol. Med. 13, 23-31
44. Vassilev, L.T., Vu, B.T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., King, N., Kammlott, U., Lukacs, C., Klein, C. et al. (2004) In vivo activation of the p53 pathway by small-molecular antagonists of MDM2. Science 303, 844-848
45. Uldrijan, S., Pannekoek, W.J. and Vousden, K.H. (2007) An essential function of the extreme C-terminus of MDM2 can be provided by MDMX. EMBO J. 26, 102-112
46. Poyurovsky, M.V., Priest, C., Kentsis, A., Borden, K.L., Pan, Z.Q., Pavletich, N. and Prives, C. (2007) The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity. EMBO J. 26, 90-101
47. Linke, K., Mace, P.D., Smith, C.A., Vaux, D.L., Silke, J. and Day, C.L. (2008) Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans. Cell Death Differ. 15, 841-848
48. Brignone, C., Bradley, K.E., Kisselev, A.F. and Grossman, S.R. (2004) A post-ubiquitination role for MDM2 and hHR23A in the p53 degradation pathway. Oncogene 23, 4121-4129
49. Mendrysa, S.M., O'Leary, K.A., McElwee, M.K., Michalowski, J., Eisenman, R.N., Powell, D.A. and Perry, M.E. (2006) Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes Dev. 20, 16-21
50. Vousden, K.H. and Lane, D.P. (2007) p53 in health and disease. Nat. Rev. Mol. Cell Biol. 8, 275-283
51. Berns, A. (2006) Cancer biology: can less be more for p53? Nature 443, 153-154
52. Culmsee, C. and Landshamer, S. (2006) Molecular insights into mechanisms of the cell death program: role in the progression of neurodegenerative disorders. Curr. Alzheimer Res. 3, 269-283
53. Jacobs, W.B., Kaplan, D.R. and Miller, F.D. (2006) The p53 family in nervous system developement and disease. J. Neurochem. 97, 1571-1584
54. Matheu, A., Maraver, A. and Serrano, M. (2008) The Arf/p53 pathway in cancer and aging. Cancer Res. 68, 6031-6034
55. Feng, Z., Hu, W., Teresky, A.K., Hernando, E., Cordon-Cardo, C. and Levine, A.J. (2007) Declining p53 function in the aging process: a possible mechanism for the increased tumor incidence in older populations. Proc. Natl. Acad. Sci. U.S.A. 104, 16633-16638
56. Hall, P.A. and Lane, D.P. (1997) Tumor suppressors: a developing role for p53? Curr. Biol. 7, R144-R147
57. Jones, R.G., Plas, D.R., Kubek, S., Buzzai, M., Mu, J., Xu, Y., Birnbaum, M.J. and Thompson, C.B. (2005) AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell 18, 283-293
58. Budanov, A.V. and Karin, M. (2008) p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell 134, 451-460
59. Mizushima, N. (2007) Autophagy: process and function. Genes Dev. 21, 2861-2873
60. Bensaad, K. and Vousden, K.H. (2007) p53: new roles in metabolism. Trends Cell Biol. 17, 286-291
61. Bensaad, K., Tsuruta, A., Selak, M.A., Vidal, M.N., Nakano, K., Bartrons, R., Gottlieb, E. and Vousden, K.H. (2006) TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126, 107-120
62. Li, H. and Jogl, G. (2009) Structural and biochemical studies of TIGAR (TP53-induced glycolysis and apoptosis regulator). J. Biol. Chem. 284, 1748-1754
63. Clem, B., Telang, S., Clem, A., Yalcin, A., Meier, J., Simmons, A., Rasku, M.A., Arumugam, S., Dean, W.L., Eaton, J. et al. (2008) Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol. Cancer Ther. 7, 110-120
64. Martindale, J.L. and Holbrook, N.J. (2002) Cellular response to oxidative stress: signaling for suicide and survival. J. Cell. Physiol. 192, 1-15
65. Sablina, A.A., Budanov, A.V., Ilyinskaya, G.V., Agapova, L.S., Kravchenko, J.E. and Chumakov, P.M. (2005) The antioxidant function of the p53 tumor suppressor gene. Nat. Med. 11, 1306-1313
66. Cano, C.E., Gommeaux, J., Pietri, S., Culcasi, M., Garcia, S., Seux, M., Barelier, S., Vasseur, S., Spoto, R.P., Pebusque, M.J. et al. (2009) Tumor protein 53-induced nuclear protein 1 is a major mediator of p53 antioxidant function. Cancer Res. 69, 219-226
67. Polyak, K., Xia, Y., Zweier, J.L., Kinzler, K.W. and Vogelstein, B. (1997) A model for p53-induced apoptosis. Nature 389, 300-305
68. Macip, S., Igarashi, M., Berggren, P., Yu, J., Lee, S.W. and Aaronson, S.A. (2003) Influence of induced reactive oxygen species in p53-mediated cell fate decisions. Mol. Cell. Biol. 23, 8576-8585
69. Rivera, A. and Maxwell, S.A. (2005) The p53-induced gene-6 (proline oxidase) mediates apoptosis through a calcineurin-dependent pathway. J. Biol. Chem. 280 29346-29354
70. Liu, Z., Lu, H., Shi, H., Du, Y., Yu, J., Gu, S., Chen, X., Liu, K.J. and Hu, C.A. (2005) PUMA overexpression induced reactive oxygen species generation and proteasome-mediated stathmin degradation in colorectal cancer cells. Cancer Res. 65, 1647-1654
71. Bertheau, P., Espie, M., Turpin, E., Lehmann, J., Plassa, L.-F., Varna, M., Janin, A. and de The, H. (2008) TP53 status and response to chemotherapy in breast cancer. Pathobiology 75, 132-139
72. Christophorou, M.A., Ringhausen, I., Finch, A.J., Brown Swigart, L. and Evan, G.I. (2006) The pathological p53-mediated response to DNA damage is distinct from p53-mediated tumor suppression. Nature 14, 214-217
73. Gudkov, A.V. and Komarova, E.A. (2005) Prospective therapeutic applications of p53 inhibitors. Biochem. Biophys. Res. Commun. 331, 726-736
74. Joerger, A.C. and Fersht, A.R. (2007) Structure-function-rescue: the diverse nature of common p53 cancer mutants. Oncogene 26, 2226-2242
75. Lozano, G. (2007) The oncogenic roles of p53 mutants in mouse models. Curr. Opin. Genet. Dev. 17, 66-70
76. Lang, G.A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, A., Parant, J.M., Valentin-Vega, Y.A., Terzian, T., Caldwell, L.C., Strong, L.C. et al. (2004) Gain-of-function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119, 861-872
77. Olive, K.P., Tuveson, D.A., Ruhe, Z.C., Yin, B., Willis, N.A., Bronson, R.T., Crowley, D. and Jacks, T. (2004) Mutant p53 gain-of-function in two mouse models of Li-Fraumeni syndrome. Cell 119, 847-860
78. Friedman, P.N., Chen, X., Bargonetti, J. and Prives, C. (1993) The p53 protein is an unusually shaped tetramer that binds directly to DNA. Proc. Natl. Acad. Sci. U.S.A. 90, 3319-3323
79. INK4a loss. Genes Dev. 22, 1337-1344
80. Weisz, L., Oren, M. and Rotter, V. (2007) Transcription regulation by mutant p53. Oncogene 26, 2202-2211
81. Li, Y. and Prives, C. (2007) Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? Oncogene 26, 2220-2225
82. Gaiddon, C., Lokshn, M., Ahn, J., Zhang, T. and Prives, C. (2001) A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol. Cell. Biol. 21, 1874-1887
83. Tomasini, R., Tsuchihara, K., Wilhelm, M., Fujitani, M., Rufini, A., Cheung, C.C., Khan, F., Itie-Youten, A., Wakeham, A., Tsao, M.S. et al. (2008) TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev. 22, 2677-2691
84. Prives, C. and White, E. (2008) Does control of mutant p53 by Mdm2 complicate cancer therapy? Genes Dev. 22, 1259-1264